Article
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.
Cancer discovery - 1 Feb 2016
Diamond Eli L, Durham Benjamin H, Haroche Julien, Yao Zhan, Ma Jing, Parikh Sameer A, Wang Zhaoming, Choi John, Kim Eunhee, Cohen-Aubart Fleur, Lee Stanley Chun-Wei, Gao Yijun, Micol Jean-Baptiste, Campbell Patrick, Walsh Michael P, Sylvester Brooke, Dolgalev Igor, Aminova Olga, Heguy Adriana, Zappile Paul, Nakitandwe Joy, Ganzel Chezi, Dalton James D, Ellison David W, Estrada-Veras Juvianee, Lacouture Mario, Gahl William A, Stephens Philip J, Miller Vincent A, Ross Jeffrey S, Ali Siraj M, Briggs Samuel R, Fasan Omotayo, Block Jared, Héritier Sebastien, Donadieu Jean, Solit David B, Hyman David M, Baselga José, Janku Filip, Taylor Barry S, Park Christopher Y, Amoura Zahir, Dogan Ahmet, Emile Jean-Francois, Rosen Neal, Gruber Tanja A, Abdel-Wahab Omar
Abstract excerpt
UNLABELLED: Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans cell histiocytosis (LCH) and non-Langerhans cell histiocytosis (non-LCH), respectively. The discovery of BRAF(V600E) mutations in approximately 50% of these patients provided the first molecular therapeutic target in histiocytosis....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.